ERBB2 and breast carcinoma: In HER2+ breast cancer SUM190 cells, neratinib treatment significantly downregulated pHER2, pAKT, pERK, and pmTOR in a time-dependent manner (Figure 4A), whereas in TNBC SUM149 cells, neratinib treatment significantly inhibited pEGFR and pERK (Figure 4B).